ArticleMedComm2022

Programmed death-ligand 1 expression on CD22-specific chimeric antigen receptor-modified T cells weakens antitumor potential.

Jie Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.